Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...

Complement 3 glomerulopathy (C3 glomerulopathy) is a very rare kidney disease. Those diagnosed with it have one of two forms of this disease: dense deposit disease (DDD) or C3 glomerulonephritis (C3GN ...

Dr Haumschild continues leading a discussion surrounding potential treatment advancements in the PNH landscape. Looking towards the future, what advancements do you anticipate in the treatment ...

(Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening ...